Stock RCKT ROCKET PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Rocket Pharmaceuticals, Inc.

Equities

RCKT

US77313F1066

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
21.85 USD -0.59% Intraday chart for Rocket Pharmaceuticals, Inc. -8.46% -27.09%
Apr. 16 Rocket Pharmaceuticals Insider Sold Shares Worth $1,945,785, According to a Recent SEC Filing MT
Apr. 11 Rocket Pharmaceuticals Insider Sold Shares Worth $308,763, According to a Recent SEC Filing MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia
BU
Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team
BU
Thinking about buying stock in Ocean Biomedical, CASI Pharmaceuticals, Cardiol Therapeutics, Geron, or Rocket Pharmaceuticals?
PR
Rocket Pharmaceuticals: Q4 Earnings Snapshot
AQ
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress
BU
Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI for the Treatment of Severe Leukocyte Adhesion Deficiency-I
AQ
Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI™ (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
BU
Rocket Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference
BU
Rocket Pharmaceuticals Appoints R. Keith Woods to Board of Directors
BU
Rocket Pharmaceuticals: Q3 Earnings Snapshot
AQ
Rocket Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Progress
BU
Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral and AAV Gene Therapies at the 30th Annual Congress of the European Society of Gene and Cell Therapy
AQ
Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral and AAV Gene Therapies at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
BU
Rocket Pharmaceuticals Announces FDA Acceptance of Biologics License Application with Priority Review for RP-L201 for the Treatment of Severe Leukocyte Adhesion Deficiency-I
AQ
Rocket Pharmaceuticals Announces FDA Acceptance of Biologics License Application with Priority Review for RP-L201 (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
BU
Rocket Pharmaceuticals to Participate in the Chardan 7th Annual Genetic Medicines Conference
BU
Rocket Pharmaceuticals, Moderna rise; American Airlines, Spirit Airlines fall, Wednesday, 9/13/2023
AQ
Rocket Pharmaceuticals Announces Pricing of Public Offering of Common Stock
BU
Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock
BU
Rocket Pharmaceuticals Reaches FDA Alignment on Pivotal Phase 2 Trial Design for RP-A501 in Danon Disease
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RCKT Stock
  4. News Rocket Pharmaceuticals, Inc.
  5. Press Releases